
    
      The trial objective is to compare chloroquine (or hydroxychloroquine) versus standard of care
      for the primary endpoint of hospitalisation or death at 28 days. Consenting adults who meet
      criteria for a Covid-19 person under investigation and who are â‰¥18 years, known to be
      HIV-positive, not requiring immediate hospitalisation and are not at risk of cardiac
      toxicities related to the study drug will be enrolled. The total sample size will be 560
      participants (280 in each arm).
    
  